Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapeutics for cancer, with its core programs built around the alpha-emitting isotope Ac-225. Its lead assets include Actimab-A for myeloid malignancies, Iomab-B for conditioning before cell therapy or transplant, Iomab-ACT for CAR-T conditioning, and ATNM-400 for additional oncology applications. The company also has a proprietary manufacturing effort aimed at producing Ac-225 more efficiently through cyclotron-based methods. Actinium has not yet generated commercial product revenue and remains dependent on clinical progress, partnerships, grants, and capital markets funding.

−40 082,2 %

−37 652,2 %

+11,1 %

6.20

6.20

— Actinium Pharmaceuticals, Inc.
%
Clinical-stage radiotherapeutic drug candidates70% Investigational oncology therapies designed to deliver radioactive payloads to cancer targets such as CD33 and CD45.
Conditioning and transplant-support programs15% Products intended to prepare patients for CAR-T therapy or stem cell transplant by depleting diseased or immune cells.
Isotope manufacturing technology10% Cyclotron-based Ac-225 production methods and related know-how used to support internal programs and future supply.
Collaborative research and grant-funded development5% NIH- and NCI-supported studies and partnered development work that help advance clinical programs.

Actinium's direct customers are not commercial end-users yet, because the company is still in clinical development and...

  • Clinical trial hospitals and cancer centersprimary

    They receive and administer Actimab-A, Iomab-B, and related investigational doses for oncology trials and early access studies.

  • Academic and government research collaboratorsprimary

    Institutions such as NCI and MSK support protocol development, clinical studies, and grant-funded research around conditioning and AML.

  • Potential licensing and commercialization partnerssecondary

    Third parties with sales forces and distribution systems may commercialize approved products in selected territories.

  • Future oncology treatment providersemerging

    If approved, hospitals and transplant centers would buy the therapies for AML, MDS, and cell-therapy conditioning use.

Actinium is headquartered in the United States and its current operating footprint is centered on U.S...

  • •United States is the core base for R&D, trials, and planned manufacturing
  • •U.S. commercialization rights are retained for Iomab-B
  • •EUMENA rights for Iomab-B were licensed to Immedica
  • •Clinical supply is delivered to large cancer hospitals, mainly in the U.S.
  • •Patent coverage extends to Canada, Europe, and Japan
  • •Future ex-U.S. growth may depend on regional partners and approvals

Actinium's strategy is to advance a small number of differentiated radiotherapeutic programs through clinical...

01
Advance Actimab-A clinical developmentshort-term

Actimab-A is the company's main value driver and needs clinical validation in AML and other myeloid malignancies.

02
Build Ac-225 manufacturing capabilitymedium-term

In-house isotope supply can reduce cost, improve reliability, and support future clinical and commercial demand.

03
Expand partnering and territory-based commercializationmedium-term

The company lacks a commercial sales infrastructure and may need partners to monetize approved products efficiently.

Actinium is a clinical-stage company with no commercial product revenue, so its business depends on successful trial...

critical

Clinical development failure

Actimab-A, Iomab-B, Iomab-ACT, and ATNM-400 are investigational and may not show sufficient efficacy or safety.

Scope
Lead oncology programs
Materiality
high
high

Regulatory delays and agency disruption

FDA, NIH, and other government actions can slow trial starts, reviews, and grant activity.

Scope
CRADA studies and future approvals
Materiality
high
high

Financing dependence

The company has no product revenue and has historically funded operations through equity issuance and grants.

Scope
Corporate liquidity
Materiality
high
high

Manufacturing and isotope supply risk

Radiotherapeutics require reliable Ac-225 production and just-in-time delivery to hospitals.

Scope
Clinical supply chain
Materiality
high
medium

Competitive pressure

Other biotech and pharmaceutical companies are developing competing oncology and radiopharmaceutical programs.

Scope
Partnering and market adoption
Materiality
medium
medium

Hazardous materials and safety liability

Radioactive and biological materials increase compliance burden and potential liability.

Scope
R&D and manufacturing operations
Materiality
medium
Grant revenue recognition
Can create uneven other revenue and margin presentation
License and milestone accounting
Revenue timing depends on regulatory and commercial achievements
Equity financing and dilution
Affects share count, cash runway, and per-share metrics
R&D expense timing
Quarterly operating loss can swing with trial activity

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

Equillium, Inc.

EQ · Pharmaceutical Preparations

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

Immunome Inc.

IMNM · Pharmaceutical Preparations

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

: 11/08/2026